PharmPK Discussion List Archive - 2012

PharmPK Discussion List Frequently Discussed Topics

A review of the new book: Quantitative Pharmacology - An Introduction to Integrative Pharmacokinetic-Pharmacodynamic Analysis
Aberrant values in Bioanalytical sample analysis
Absplots Absorption Program and Rate of Absorption
Accumulation index Calculation
Acetylcysteine
Aescin and Tetracaine BCS
Algorithm of Best Fit in Phoenix WinNonLin
Analysis of bolus plus continuous infusion data without elimination samples
Announcement for Basic PK Workshop 2013
Approvals based on M&S
Assays with large CVs
AUC linearity
AUMC
Availability of manual for SAAM
BCS with low water solubility
BE study for artemether and lumefantrine
BE study for ASEAN Market
Bioanalytical lab for quantitation of Fatty acids by GC or GC-MS in clinical samples
Bioanalytical method for creatinine in human urine
Bioequivalence based on metabolite only and not parent compound
Bioequivalence in cancer patients
Bioequivalence studies of Omeprazole Magnesium MUPS tablets
Bioequivalence studies required for Inhaler products
Bioequivalence study on zolpiderm
Book on Physiologically-based pharmacokinetic (PBPK) modelling
Calculation of biological half-life for dermal product
Carvedilol absorption mechanism
CB2 antagonist-inverse agonist PK-PD data
CL and V
CL, V and drug-drug interaction
Classical and Westlake methods in calculation of CI
Clonazepam PK
Clopidogrel - highly variable drug
Clopidogrel Analysis
Combining single dose PK study with multiple dose PK study
Cyclosporine therapeutic range
CYP induction
DCGI approval procedure-BA/BE studies
Designing in vivo xenograft study
Determination of CLint from Km and Vmax
Determining wash-out period in BE study
Difference between NCA and PK model for IP study in mice
Different weighing factor in single study
Drug Interaction CL and V
Early concentrations after IV
Effect of alcohol on in vivo bioavailabilty from CR dosage forms
ELISA GLP Method
EMA Guideline-Analytical run, batch and acceptance
Emax and Cmax - parameters and statistics
Endogenous Molecules
Enterohepatic circulation
Enterohepatic circulation using phoenix
Equilibrium dialysis: Time to reach equilibrium
Error message in ADAPT II
Escitalopram BCS Classification
Estimate plasma concentration from non-compartmental variables
EU 90% CI acceptance criteria for Tacrolimus
Exclusion of ULOQ
Experimental pharmacology for pharmacy students
Extending Calibration curve range
Formulation with longer contact time with the gingival mucosa
Fulvestrant Dissolution method and media
GI toxic
GLP requirements for PK bioanalytical work for phase I/II studies
GMP Requirement for an Oral 14-C ADME Study in Man
Gradient versus isocratic peak
Half-life of Ivermectin
Health canada BE guideline-Corrected and uncorrected data BE acceptance
High inert metabolite concentrations in humans
How to get model of multiple dose levels
How to Validate PK-PD software
How to write "Sequence/Sleep" statement in Phoenix WinNonlin
Increased AUC but constant clearance after multiple doses
Incurred sample analysis (case study)
Interaction of SSRIs with fentanyl
Interaction with midazolam
International Journal of Health and Pharmaceutical Sciences (IJHPS)
International Society of Pharmacometrics
Intravenous Administration of Clarithromycin in Human
Intravenous P-gp or CYP inhibitor affecting first pass of an Oral P-gp or CYP3A4
ISR for an AMS method
IV Study for Oral Only Drug
IVIVC
K-PD models
Limitations of NCA of biotech drugs
Linear Mixed Effects Model in Phoenix
Lipid based formulation: Discriminating Dissolution Media
List of Drugs with Saturable Protein Binding
List of Preferred Vehicles
Lymph flow to the tissues
Lymph volume and flow rate
Lymphatic absorption of Solid Lipid Nanoparticles
MAO Content in S9, LM and Liver mitochondria
MAO-B substrate
Maxsim2_2.0 Interactive PKPD Simulation
Mechanism of higher dose normalized AUC and oral CL at lower dosage
Mechanistic vs semi-mechanistic
Midazolam DDI Design
Model substrate for P-gp with a twist
Model validation
Monkey oral formulation
Multiple routes NCA analysis in a single run using Phoenix Winnonlin
N for single dose formulation NCA PK given once (ever)
Negative control marker for LECs and drug permeability assay
New article on IVIVC by FDA
New book: Quantitative Pharmacology - An Introduction to Integrative
New eBook available - Basic Pharmacokinetics
Non-CYP mediated metabolism assay
Olanzapine double peak
Only Metabolite data for EU BE study
PBPK model books
PBPK modeling CL calculation method
PBPK models
Percent Purity
Permeability - PAMPA vs Caco-2
PFIM - error message
PFIM Sampling time
Pharmacokinetic study in Hepatic Impairment patients
Phase II conjugates in FDA newly-issued draft DDI guidance
Phoenix NLME Pop Theta CV% Estimates
PK Book update - Basic Pharmacokinetics: Truncated
PK study of novel nasal formulation with BCS II drug
PK textbooks in non-English languages
PKPD course announcement
PKsolver
Plasma drug concentration profile
Plasma protein binding in vivo
Plasma recovery
Plasma versus Serum Protein Binding
Polynomial UIR function
PopPK presentations - the good, the bad, and the ugly
Post study safety sample
Post-dosing period prior to feeding in BE study
Post-mortem drug concentrations
Predose conc
Protein binding centrifuge speed
Protein binding mouse strain difference
Quantification of naringin and naringinin in biological fluids in animal models
Rat Synovial fluid volume
Reference scaled BE
Regarding gingival delivery or administration
Regional weight of enterocytes in colon
Relevance of TTT method vs Best fit method in WNL 6.2
Repeated dose Tissue distribution study
Repeated IP Injections to Mice
Reserve drug samples to be shipped to the clinical site
Salt PK Versus free base PK
Sample size for a population PK study in a Kenyan Cohort
Scaled average bioequivalence
Second order reaction
Selection of dose for dermal application
Significant period effect
Stability studies for ANVISA submission
Streptomycin for TB
Subject Selection criteria for BE study for China
TDM - non-antibody based TDM for novel Aminoglycoside
Textbook for Pharmacodynamics
Textbook on highly variable drugs - statistics
Textbook on population pharmacokinetics
Three compartment model
Three PK/PD events
Tightening of BE limits for NTI
Timing of rifampicin dosing to investigate OATP1B3-inhibition
Two square root two CV criteria
Variability in PK profile of NCEs by SC route of administration
Varying retention times LC MS/MS
Vd and Cl for intraperitoneal, and intramuscular administration are not necessary
WinNonlin - Model 5 (K01 = K10)

Visit the PharmPK Website for more information

Support PharmPK by using the
link to buy books etc.
from Amazon.com